Literature DB >> 21718327

PET/CT in diagnosis of movement disorders.

Valentina Berti1, Alberto Pupi, Lisa Mosconi.   

Abstract

Molecular imaging with PET offers a broad variety of tools supporting the diagnosis of movement disorders. The more widely applied PET imaging techniques have focused on the assessment of neurotransmitter systems, predominantly the pre- and postsynaptic dopaminergic system. Additionally, PET imaging with [(18) F]fluorodeoxyglucose has been extensively used to assess local synaptic activity in the resting state and to highlight local changes in brain metabolism accompanying changes in neural activity in movement disorders. PET imaging has provided us with diagnostic agents as well as tools for evaluation of novel therapeutics, and has served as a powerful means for revealing in vivo changes at different stages of movement disorders and within the course of an individual patient's illness.
© 2011 New York Academy of Sciences.

Entities:  

Mesh：

Year:  2011        PMID： 21718327      PMCID： PMC3692301          DOI： 10.1111/j.1749-6632.2011.06025.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  100 in total

1.  PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration.

Authors:  H Nagasawa; H Tanji; H Nomura; H Saito; Y Itoyama; I Kimura; S Tuji; T Fujiwara; R Iwata; M Itoh; T Ido
Journal:  J Neurol Sci       Date:  1996-08       Impact factor: 3.181

2.  Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography.

Authors:  S Gilman; K A Frey; R A Koeppe; L Junck; R Little; T M Vander Borght; M Lohman; S Martorello; L C Lee; D M Jewett; M R Kilbourn
Journal:  Ann Neurol       Date:  1996-12       Impact factor: 10.422

3.  Recent advances in heritable ataxias.

Authors:  O Hurko
Journal:  Ann Neurol       Date:  1997-01       Impact factor: 10.422

4.  Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.

Authors:  A Antonini; K L Leenders; R Spiegel; D Meier; P Vontobel; M Weigell-Weber; R Sanchez-Pernaute; J G de Yébenez; P Boesiger; A Weindl; R P Maguire
Journal:  Brain       Date:  1996-12       Impact factor: 13.501

5.  In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.

Authors:  N Turjanski; A J Lees; D J Brooks
Journal:  Neurology       Date:  1997-09       Impact factor: 9.910

6.  Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia.

Authors:  J S Perlmutter; M K Stambuk; J Markham; K J Black; L McGee-Minnich; J Jankovic; S M Moerlein
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

7.  Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes.

Authors:  L Bäckman; T B Robins-Wahlin; A Lundin; N Ginovart; L Farde
Journal:  Brain       Date:  1997-12       Impact factor: 13.501

8.  Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.

Authors:  A Antonini; K L Leenders; P Vontobel; R P Maguire; J Missimer; M Psylla; I Günther
Journal:  Brain       Date:  1997-12       Impact factor: 13.501

9.  Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomographic study.

Authors:  M Otsuka; Y Ichiya; Y Kuwabara; S Hosokawa; M Sasaki; T Yoshida; T Fukumura; M Kato; K Masuda
Journal:  J Neurol Sci       Date:  1996-12       Impact factor: 3.181

10.  Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.

Authors:  K A Frey; R A Koeppe; M R Kilbourn; T M Vander Borght; R L Albin; S Gilman; D E Kuhl
Journal:  Ann Neurol       Date:  1996-12       Impact factor: 10.422
View more
  16 in total

1.  Paraneoplastic Atypical Parkinsonism with Anti-CRMP5 Antibodies and Severe Caudate and Putaminal Hypometabolism on 18-Fluorodeoxyglucose Positron Emission Tomography of the Brain.

Authors:  Siew Mei Yap; Tim Lynch; Peter MacMahon; Brian Murray
Journal:  Mov Disord Clin Pract       Date:  2016-06-06

2.  Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.

Authors:  Jan Rusz; Cecilia Bonnet; Jiří Klempíř; Tereza Tykalová; Eva Baborová; Michal Novotný; Aaron Rulseh; Evžen Růžička
Journal:  J Neurol       Date:  2015-02-17       Impact factor: 4.849

Review 3.  Neurophysiology and neurochemistry of corticobasal syndrome.

Authors:  Aditya A Murgai; Mandar S Jog
Journal:  J Neurol       Date:  2018-01-06       Impact factor: 4.849

4.  Abnormal high-frequency burst firing of cerebellar neurons in rapid-onset dystonia-parkinsonism.

Authors:  Rachel Fremont; D Paola Calderon; Sara Maleki; Kamran Khodakhah
Journal:  J Neurosci       Date:  2014-08-27       Impact factor: 6.167

Review 5.  PET Neuroimaging: Insights on Dystonia and Tourette Syndrome and Potential Applications.

Authors:  Pierpaolo Alongi; Leonardo Iaccarino; Daniela Perani
Journal:  Front Neurol       Date:  2014-09-23       Impact factor: 4.003

6.  Proposed Motor Scoring System in a Porcine Model of Parkinson's Disease induced by Chronic Subcutaneous Injection of MPTP.

Authors:  Joon Ho Moon; Ji Ho Kim; Hyung-Jun Im; Dong Soo Lee; Eun Jung Park; Kilyoung Song; Hyun Ju Oh; Su Bin Hyun; Sang Chul Kang; Hyunil Kim; Hyo Eun Moon; Hyung Woo Park; Hong Jae Lee; Eun Ji Kim; Seokjoong Kim; Byeong Chun Lee; Sun Ha Paek
Journal:  Exp Neurobiol       Date:  2014-09-18       Impact factor: 3.261

7.  Cortical dynamics within and between parietal and motor cortex in essential tremor.

Authors:  Arnab Roy; Stephen A Coombes; Jae Woo Chung; Derek B Archer; Michael S Okun; Christopher W Hess; Aparna Wagle Shukla; David E Vaillancourt
Journal:  Mov Disord       Date:  2018-10-21       Impact factor: 10.338

8.  Crossed cerebellar diaschisis on 18F-FDG PET: Frequency across neurodegenerative syndromes and association with 11C-PIB and 18F-Flortaucipir.

Authors:  Karine Provost; Renaud La Joie; Amelia Strom; Leonardo Iaccarino; Lauren Edwards; Taylor J Mellinger; Julie Pham; Suzanne L Baker; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  J Cereb Blood Flow Metab       Date:  2021-03-10       Impact factor: 6.200

Review 9.  A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis.

Authors:  Daniela Perani; Perani Daniela; Orazio Schillaci; Schillaci Orazio; Alessandro Padovani; Padovani Alessandro; Flavio Mariano Nobili; Nobili Flavio Mariano; Leonardo Iaccarino; Iaccarino Leonardo; Pasquale Anthony Della Rosa; Della Rosa Pasquale Anthony; Giovanni Frisoni; Frisoni Giovanni; Carlo Caltagirone; Caltagirone Carlo
Journal:  Biomed Res Int       Date:  2014-03-19       Impact factor: 3.411

10.  Effect of Age and Disease Duration on the Levodopa Response in Patients with Advanced Parkinson's Disease for Deep Brain Stimulation of the Subthalamic Nucleus.

Authors:  Dursun Aygun; Ersoy Kocabicak; Mustafa Onur Yildiz; Yasin Temel
Journal:  Front Neurol       Date:  2016-06-27       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.